This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 3 trials Clear all
Filter by:

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

  • Status Recruiting
    Recruiting
  • Condition Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
    Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: CC-90009

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: CC-90009

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Yale Cancer Center, New Haven, Connecticut, United States

Brief Summary

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory high-risk myelodysplastic syndrome.

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

  • Status Recruiting
    Recruiting
  • Condition Leukemia, Myeloid, Acute
    Leukemia, Myeloid, Acute
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: CC-90009, Drug: Venetoclax, Drug: Azacitidine, Drug: Gilteritinib

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: CC-90009, Drug: Venetoclax, Drug: Azacitidine, Drug: Gilteritinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of California, San Francisco, San Francisco, California, United States

Brief Summary

CC-90009-AML-002 is an exploratory Phase 1b open-label multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in subjects with acute myeloid leukemia (AML).

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

  • Status Recruiting
    Recruiting
  • Condition Healthy Volunteer
    Healthy Volunteer
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: CC-90009, Radiation: [14C]

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: Male
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: CC-90009, Radiation: [14C]

Eligibility
  • Ages:
  • Sexes: Male
  • Accepts Healthy Volunteers:
Locations

Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

Brief Summary

CC-90009-CP-001 is a Phase 1, single-center, open-label, clinical pharmacology study to measure how much CC 90009 gets into the bloodstream, how much is eliminated in urine and stool, and how long it takes the body to get rid of it. In addition, the safety and tolerability of CC 90009 will be evaluated.